Cristina Maccalli, PhD

Principal Investigator – Assistant Level Laboratory of Immune Biological Therapy

Email: cmaccalli (@)

SELECTED PUBLICATIONS(equal contribution, *corresponding):

  1. Tomei S, Ibnaof O, Ravindran S, Ferrone S, Maccalli C*. Cancer Stem Cells Are Possible Key Players in Regulating Anti-Tumor Immune Responses: The Role of Immunomodulating Molecules and MicroRNAs. Cancers (Basel). 13:1674. doi: 10.3390/cancers13071674. 
  2. Tomei S, Volontè A, Ravindran S, Mazzoleni S, Wang E, Galli R, Maccalli C. MicroRNA Expression Profile Distinguishes Glioblastoma Stem Cells from Differentiated Tumor Cells. J Pers Med. 2021 11:264. doi: 10.3390/jpm11040264.
  3.  Guerrouahen B., Elnaggar M., Al-Mohannadi A., Kizhakayil D., Bonini C., Reuben B., Brentjer R., Buchholz C., Casorati G., Ferrone S., Locke F., Martin F., Schambach A., Turtle C., Veys P., van der Vliet A.J-J.-EICCI Faculty, Maccalli C.* “Proceedings from the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): from Discovery to Off-the-Shelf Development. Front. Immunol., 14 January 2021
  4.  Maccalli C. Translational cancer biology. 2020. J Transl Med. Sep 23;18(1):364. doi: 10.1186/s12967-020-02537-z.
  5. Pilla L., Alberti A., Di Mauro P., Gemelli M., Cogliati V., Cazzaniga ME., BidoliP. and Maccalli C. “Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future ProspectsCancers 2020, 12(11), 3456; - 20 Nov 2020.
  6.  Lieskovan S-H., Bhaumik S., Dhodapkar K., Grivel J-C., Gupta S., Hanks BA., Janetzki S., O Kleen T., Koguchi Y., Lund AW., Maccalli C., Mahnke YD., Novosiadly RD., Selvan S.R., Sims T., Zhao Y. and Maecker HT. SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery “ J. Immunoth. Cancer, December 2020 (Position marker and guideline) 
  7. Gotti M., Defrancesco I., D'angelo M., Basso S., Crotto L., Marinelli A., Maccalli C., Iaconianni V. “Cancer Immunotherapy using Chimeric Antigen Receptor (CAR) expressing T cells: present and future needs of clinical cancer centers”.  Frontiers in Immunology. 
  8. Rovida A., Maccalli C., Scarfò L., Dellabona P., Stamatopoulos K. and Ghia P. “Exploiting B Cell Receptor Stereotypy to design Tailored Immunotherapy in Chronic Lymphocytic Leukemia” DOI: 10.1158/1078-0432.CCR-20-1632
  9. Guerrouahen BS, Maccalli C, Cugno C, Rutella S, Akporiaye ET. Reverting Immune Suppression to Enhance Cancer Immunotherapy. Front Oncol. 2020 Jan 21;9:1554. doi: 10.3389/fonc.2019.01554. eCollection 2019.
  10. Ravindran S, Rasool S, Maccalli C*. The Cross Talk between Cancer Stem Cells/Cancer Initiating Cells and Tumor Microenvironment: The Missing Piece of the Puzzle for the Efficient Targeting of these Cells with Immunotherapy. Cancer Microenviron. 2019 Nov 22. doi: 10.1007/s12307-019-00233-1.
  11. Maccalli C*, Rasul K, Elawad M, Ferrone S. The role of cancer stem cells in the modulation of anti-tumor immune responses. Semin Cancer Biol. 2018 Sep 24. pii: S1044-579X(18)30044-0. doi: 10.1016/j.semcancer.2018.09.006.
  12.  Pilla L, Maccalli C*. Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges. Biomedicines. 2018 Jul 2;6(3). pii: E76. doi: 10.3390/biomedicines6030076.
  13. Pilla L, Ferrone S, Maccalli C*. Methods for improving the immunogenicity and efficacy of cancer vaccines. Expert Opin Biol Ther. 2018 Jul;18(7):765-784. doi: 10.1080/14712598.2018.1485649. Epub 2018 Jun 17.